Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:6193
Name epithelioid sarcoma
Definition A connective tissue cancer that is characterized by the presence of epithelioid cells forming nodular patterns and has_material_basis_in mesenchymal tissue.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer epithelioid sarcoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
SMARCB1 negative Tazemetostat epithelioid sarcoma predicted - sensitive detail...
SMARCB1 inact mut N/A epithelioid sarcoma not applicable detail...
SMARCB1 del N/A epithelioid sarcoma not applicable detail...
SMARCB1 loss Barasertib epithelioid sarcoma sensitive detail...
RB1 I124Rfs*6 RB1 del SMARCB1 loss Tazemetostat epithelioid sarcoma predicted - resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02275286 Phase Ib/II Trabectedin Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) Recruiting ITA | FRA | ESP 0
NCT02584309 Phase II Dexrazoxane Doxorubicin + Olaratumab Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Completed USA 0
NCT02601937 Phase I Tazemetostat A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma Completed USA | NLD | ITA | GBR | FRA | DNK | DEU | CAN | AUS 0
NCT02601950 Phase II Tazemetostat A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma Completed USA | ITA | GBR | FRA | DEU | CAN | BEL | AUS 1
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT03009201 Phase I Doxorubicin + Ribociclib Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Completed USA 0
NCT04204941 Phase III Doxorubicin Doxorubicin + Tazemetostat Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma Recruiting USA | GBR | CAN 1
NCT04216953 Phase Ib/II Atezolizumab + Cobimetinib MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma (COTESARC) Active, not recruiting FRA 0
NCT04416568 Phase II Ipilimumab + Nivolumab Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers Recruiting USA 0
NCT04741438 Phase III Ipilimumab + Nivolumab Pazopanib Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) Recruiting FRA 0
NCT04965753 Phase I FHD-609 FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors Terminated USA | ITA | FRA | ESP 0
NCT04996004 Phase Ib/II Doxorubicin + TTI-621 A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma Terminated USA 0
NCT05286801 Phase Ib/II Atezolizumab + Tiragolumab Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Recruiting USA | CAN | AUS 0
NCT05407441 Phase Ib/II Ipilimumab + Nivolumab + Tazemetostat Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors Recruiting USA 0
NCT06444880 Phase II Cemiplimab + REGN4018 REGN4018 Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies Recruiting USA 0